Key result
IVIG lots manufactured from US Source plasma had significantly higher neutralization titers against echovirus 11 and 30 compared to US Recovered plasma (P<0.0001).
Population
41 IVIG lots manufactured from either whole blood or collected by apheresis and from either the US or EU
Comparison
In vitro neutralization assays against echovirus… vs Comparison between plasma collection practices…
Design
Preclinical
Authors
Loading...
May inform IVIG lot selection for echovirus; leaves open clinical benefit in humans.
p-value: p=<0.0001
IVIG lots differ in their neutralizing antibody content against different echovirus serotypes depending on plasma collection practices and geographic origin, suggesting lot selection could optimize treatment of break-through infections.
Planitzer et al. (2010) studied Echovirus break-through infections in antibody deficiencies (n=41). IVIG lots from US Source plasma or US plasma vs. IVIG lots from US Recovered plasma or EU plasma was evaluated on Echovirus serotype-specific neutralization titers (E 9, E 11, E 13, and E 30) (p=<0.0001). IVIG lots manufactured from US Source plasma had significantly higher neutralization titers against echovirus 11 and 30 compared to US Recovered plasma (P<0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: